Accelerated Round Completion Positions Company for New Drug Application (NDA) Submission and Commercial Launch Partnerships
Read MoreAs announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating MVID patient by up to 27%; abstract describing results accepted for presentation at upcoming North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2025 Annual Meeting in Chicago
Read MoreFollowing FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025
Read More~ The Summit is the Premier Industry Event for Defining How New Product Planning Teams and Related Functions Make Informed, Value-Based, Data-Driven Decisions ~
~ Ensysce Biopharma Leader to Deliver Opening Remarks and Present Case Study on Launching Successful Brands ~
Read More
DEA Administrator Terrance Cole has also signaled a tough line: "Everybody knows my stance on marijuana after 30 plus years in law enforcement, so don't even ask!" However, with all due respect to law enforcement, you can't fight a disease with a badge.
MMJ is developing FDA regulated medicine, not an illicit substance. We are the science, and our mission is to treat patients, not to police a plant." Duane Boise, CEO MMJ International Holdings.
Read More
According to the NIH, Acute myocardial infarction (AMI) is a major cause of death, affecting nearly 3 million Americans each year and resulting in over a million deaths
Trial demonstrates dramatically higher and more rapid therapeutic impact compared to standard chewed aspirin tablets in clinical trial
Aspire's sublingual aspirin was safe and well-tolerated
Aspire plans to review clinical trial results with the FDA to enable a potential regulatory submission for accelerated approval
"As President Trump weighs marijuana rescheduling in the coming weeks, the DEA's track record reveals years of mismanagement, empty promises, and patients left waiting," stated MMJ CEO Duane Boise.
Read More
New BlueFletch Healthcare solution transforms clinical workflow efficiency while supporting healthcare organizations' regulatory compliance requirements
Read More
The untold truth? Rescheduling may not save the cannabis industry-it could divide it.
Past IRS 280E tax liabilities won't vanish-some companies owe hundreds of millions.
Interstate cannabis operators still remain barred from DEA licensing, regardless of tax changes.
Marijuana is still DEA regulated under the Controlled Substance Act and
The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately 35% versus net Q1 2025 revenue of approximately $2.2 million and increased approximately 10% versus net Q2 2024 revenue of approximately $2.7 million
Mytesi prescription volume increased approximately 6.5% in Q2 2025 over Q1 2025 and Mytesi prescription volume in Q2 2025 was equal to the volume in Q2 2024
As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome (SBS-IF) patient by up to 12.5%; FDA meeting resulted in planned Jaguar regulatory pathway to complete supplemental NDA strategy for crofelemer for patients with metastatic breast cancer, a population meeting orphan definition in US
Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's orphan indication products, resulting in non-dilutive funding for Jaguar
REMINDER: Today Jaguar to host investor webcast at 8:30 a.m. Eastern regarding Q2 2025 financials and company updates; Click here to register
Read MoreCompany Reports Quarterly Revenue of $1.2 Million; Net Loss and Loss per Diluted Share of $2.2 Million and $2.13
Quarterly Adjusted EBITDA Loss of $1.7 Million Reflects 40% YOY Improvement
TRNR held 29.6 Million FET tokens as of June 30, 2025 and 67.4 Million FET tokens as of August 13, 2025, with a value in excess of $50 million, representing the largest publicly traded AI-focused Digital Asset Treasury
Stockholders' Equity Was $16.3 Million at Quarter End
2025 Pro Forma Revenue Guidance Increased to more than $80 Million, driven by Sportstech's Stronger-Than-Expected Performance, and Fourth Quarter Profitability Guidance Reiterated
Read More- Dermata announced additional positive data from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial-
- Raised $8.8 million in gross proceeds from a private placement and warrant inducement financings during the first half of 2025 -
Read MoreInitiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Approval
Receives $5.3 Million Installment from NIDA To Support Overdose Protection Program
Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
Read More
BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout to help athletes and fitness enthusiasts maximize their performance potential
30,000 BUZZ BOMB™ sample packs of four 50mg stick packs in each flavor distributed to convention attendees
Well-known fitness instructors, fitness celebrities, athletes, and influencers along with thousands of fitness enthusiasts and consumers sampled BUZZ BOMB™'s four bold flavors
As part of its launch, Aspire plans on partnering with well-known athletes and influencers across fitness training and endurance sports to accelerate consumer awareness and uptake
BUZZ BOMB™ is available for purchase at buzzbomb.buzz, the Company's new E-commerce website
Builds on the targeted immune activation model validated by mipletamig in AML, adapted for prostate cancer.
Engineered for precision T-cell activation in prostate cancer; part of Aptevo's growing CRIS-7-derived CD3 portfolio targeting both hematologic and solid tumors
Read More
